Revive's lead product is in the treatment for acute gout flares, which completed a Phase 2a study in the U.S.
Revive Therapeutics Announces Issuance of U.S. Patent Related to Bucillamine in the Treatment of Gout
Revive Therapeutics to Present at Noble Capital Markets' Investor Conference
Revive Therapeutics Announces DTC Eligibility of Its Common Shares
Revive Therapeutics Retains the Ruth Group to Build U.S. Investment Community Awareness
Revive Therapeutics Announces Positive Final Results from Its Phase 2a Study for the Treatment of Acute Gout Flares